Comorbidities and Race/Ethnicity Among Adults with Stimulant Use Disorders in Residential Treatment by Sanchez, Katherine et al.
Virginia Commonwealth University
VCU Scholars Compass
Social Work Publications School of Social Work
2015
Comorbidities and Race/Ethnicity Among Adults
with Stimulant Use Disorders in Residential
Treatment
Katherine Sanchez
University of Texas at Arlington
Karen G. Chartier
Virginia Commonwealth University
Tracy L. Greer
University of Texas Southwestern Medical Center
See next page for additional authors
Follow this and additional works at: https://scholarscompass.vcu.edu/socialwork_pubs
Part of the Social Work Commons
This Article is brought to you for free and open access by the School of Social Work at VCU Scholars Compass. It has been accepted for inclusion in
Social Work Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
https://scholarscompass.vcu.edu/socialwork_pubs/27
Authors
Katherine Sanchez, Karen G. Chartier, Tracy L. Greer, Robrina Walker, Thomas Carmody, and Chad D.
Rethorst
This article is available at VCU Scholars Compass: https://scholarscompass.vcu.edu/socialwork_pubs/27
Comorbidities and Race/Ethnicity Among Adults with Stimulant 
Use Disorders in Residential Treatment
Katherine Sanchez,
The University of Texas at Arlington, Arlington, Texas
Karen G. Chartier,
Virginia Commonwealth University, Richmond, Virginia
Tracy L. Greer,
University of Texas Southwestern Medical Center, Dallas, Texas
Robrina Walker,
University of Texas Southwestern Medical Center, Dallas, Texas
Thomas Carmody,
University of Texas Southwestern Medical Center, Dallas, Texas
Chad D. Rethorst,
University of Texas Southwestern Medical Center, Dallas, Texas
Kolette M. Ring,
University of Texas Southwestern Medical Center, Dallas, Texas
Adriane M. Dela Cruz, and
University of Texas Southwestern Medical Center, Dallas, Texas
Madhukar H. Trivedi
University of Texas Southwestern Medical Center, Dallas, Texas
Abstract
Comorbid physical and mental health problems are associated with poorer substance abuse 
treatment outcomes; however, little is known about these conditions among stimulant abusers at 
treatment entry. This study compared racial and ethnic groups on baseline measures of drug use 
patterns, comorbid physical and mental health disorders, quality of life, and daily functioning 
among cocaine and stimulant abusing/dependent patients. Baseline data from a multi-site 
randomized clinical trial of vigorous exercise as a treatment strategy for a diverse population of 
stimulant abusers (N = 290) were analyzed. Significant differences between groups were found on 
drug use characteristics, stimulant use disorders, and comorbid mental and physical health 
conditions. Findings highlight the importance of integrating health and mental health services into 
substance abuse treatment and could help identify potential areas for intervention to improve 
treatment outcomes for racial and ethnic minority groups.
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INTRODUCTION
U.S. population surveys and treatment studies indicate there are racial and ethnic differences 
in the prevalence of substance use and participation in substance abuse treatment (Substance 
Abuse and Mental Health Services Administration, 2008, 2010). The National Institute on 
Drug Abuse (NIDA) reports that racial and ethnic minorities comprise 40% of admissions to 
publicly funded substance abuse treatment programs (National Institue on Drug Abuse, 
2011). Recent research suggests these populations may be at particular risk for poor 
treatment outcomes, largely due to socioeconomic factors (Saloner & Le Cook, 2013). 
Despite well-described difficulties in fulfilling the National Institutes of Health’s required 
inclusion of racial and ethnic minorities in the design and conduct of clinical trials (Arean, 
Alvidrez, Nery, Estes, & Linkins, 2003; Yancey, Ortega, & Kumanyika, 2006), the NIDA 
Clinical Trials Network (CTN) has continually demonstrated success in the recruitment and 
retention of these populations (Burlew et al., 2011; Carroll et al., 2007). As such, the CTN 
offers a unique opportunity to better characterize racial and ethnic minorities in treatment 
and detect differences in the needs of underserved populations. In particular, this study 
examined racial and ethnic differences in the physical and mental health conditions often 
comorbid with stimulant abuse/dependence.
Previous evidence from the CTN shows marked heterogeneity in diagnosed stimulant users, 
with differences in use patterns and subtypes among racial and ethnic minorities (Wu et al., 
2009). In one multisite study of treatment-seeking adults, most stimulant users were Black 
and used cocaine only, whereas primary amphetamine users were more likely to be White or 
Hispanic. In fact, there were no Black participants among amphetamine users in the study. 
In addition, amphetamine users were more likely than cocaine users to be court-ordered to 
treatment and to be on probation or parole (Wu et al., 2009).
Comorbid Physical Health Conditions
Among patients seeking treatment for substance abuse, the comorbid medical illness burden 
is far greater than for the general population, possibly due to lack of access to primary care 
(De Alba, Samet, & Saitz, 2004). In addition, there is significant evidence that racial and 
ethnic minority populations are generally less likely to receive a variety of medical services. 
These disparities hold even when controlling for insurance status, income, age, and 
education level (Institute of Medicine, 2003) and are amplified in the presence of substance 
abuse and comorbid psychiatric disorders (De Alba et al., 2004; Druss & von Esenwein, 
2006). Anywhere from 45% to 70% of people with drug addictions report having at least 
one chronic medical illness (Chang et al., 2010) and many people have poly-substance 
dependence resulting in combined risks for multiple medical illnesses (Wadland & 
Ferenchick, 2004). Comorbid mental health disorders and physical health problems 
negatively affect treatment outcomes via early dropout and relapse (Compton, Cottler, 
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Jacobs, Ben-Abdallah, & Spitznagel, 2003; Druss & von Esenwein, 2006; Kessler et al., 
2003).
Comorbid Mental Health Conditions
The presence of mental health disorders in the context of substance dependence is associated 
with greater illness severity and substantial disability (Compton et al., 2003; Compton, 
Thomas, Stinson, & Grant, 2007; L. Davis et al., 2012; Nunes & Levin, 2004). Individuals 
with substance use disorders endorse greater depression symptom severity, length of illness, 
likelihood of anxious features, and worse remission/response outcomes with treatment 
(Compton et al., 2007; K. Davis, Schoenbaum, & Audet, 2005). Major depression predicts a 
greater number of substances used, and alcohol dependence and generalized anxiety disorder 
both predict higher rates of drug dependence diagnoses (Compton et al., 2003). The 
physical, mental, and legal consequences of drug use are far greater for racial and ethnic 
minorities, and the presence of multiple disorders at baseline predicts worse substance abuse 
treatment outcomes (Burlew, Feaster, Brecht, & Hubbard, 2009).
The Current Study
The current study compared racial and ethnic groups on baseline measures of drug use 
patterns, comorbid physical and mental health disorders, quality of life, and daily 
functioning among participants in the Stimulant Reduction Intervention using Dosed 
Exercise (CTN-0037) trial, a multisite randomized clinical trial implemented through the 
NIDA’s National Drug Abuse Treatment CTN. The trial aimed to test a novel approach to 
the treatment of stimulant abuse via the addition of vigorous exercise compared to health 
education as a treatment strategy for stimulant abuse or dependence (Trivedi, Greer, et al., 
2011). CTN-0037 hypothesized that exercise has the potential to improve other health 
domains that might be adversely affected by stimulant use or its treatment, such as sleep 
disturbance, cognitive function, mood, weight gain, quality of life, and anhedonia.
For the current study, we hypothesized that racial and ethnic groups would use different 
substances and report different patterns of drug use resulting in different rates of stimulant 
use disorder diagnosis. We also expected the presence of comorbid mental health diagnoses 
to be more prevalent and severity of depression to be greater among racial and ethnic 
minority populations and to correspond with poor physical health functioning and quality of 
life in this sample of stimulant abusing/dependent patients in residential treatment.
METHODS
Study Sample and Procedures
Participants were recruited from 9 geographically diverse, community-based substance 
abuse treatment programs across the United States and were enrolled in the multi-site 
Stimulant Reduction Intervention using Dosed Exercise (CTN-0037) trial within the NIDA 
National Drug Abuse Treatment CTN. The NIDA CTN framework consists of 13 research 
nodes across the United States that partner with a variety of community-based treatment 
programs. The CTN provides a broad infrastructure for rapid, multisite testing of promising 
science-based therapies and the subsequent delivery of these treatments to patients in 
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community-based treatment. Details of the study rationale and design have been previously 
published (Trivedi, Greer, et al., 2011). The study was reviewed and approved by the 
Institutional Review Board (IRB) at University of Texas Southwestern Medical Center, as 
well as the IRBs of each of the participating treatment programs. All participants provided 
written informed consent.
Trial site selection criteria were broad, with the goal of testing the intervention in a wide 
range of outpatient substance abuse populations, and geographic location was an important 
consideration in enhancing representation in the trial. Selected sites had a residential 
component and length of stay generally between 21 and 30 days. Other site characteristics 
included a requirement of no formal exercise program as a component of treatment and 
availability of outpatient treatment at or near the residential setting where the study was 
located so that it was feasible for participants to return to the study site to complete study 
activities for the full 9 months of the study (Trivedi, Greer, et al., 2011; Warden et al., 
2012).
Eligible participants were those reporting illicit stimulant drug use (e.g., cocaine, 
methamphetamine, or amphetamine) within the 30 days prior to admission to residential 
treatment and who received medical clearance for exercise through a protocol-defined 
maximal exercise test (in accordance with American College of Sports Medicine (2010) 
guidelines), medical history, and physical examination from protocol-approved medical 
personnel. Participants with general medical conditions that contraindicated exercise and 
those with psychosis or other psychiatric conditions that posed a safety risk were excluded 
(Trivedi, Greer, et al., 2011).
This analysis included data collected during the baseline evaluation (N = 290) for 
participants who self-identified as non-Hispanic Black (n = 128), non-Hispanic White (n = 
131), or Hispanic (n = 31). Individuals identifying multiple races (n = 8) or “other” (n = 4) 
were too few to analyze and were excluded. Recruited individuals were diagnosed with 
stimulant abuse or dependence (i.e., cocaine, methamphetamine, amphetamine or other 
stimulant, except caffeine or nicotine) as defined by Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (American Psychiatric 
Association, 2000). Those with opioid dependence were excluded from participation. 
Eligible participants were randomized to one of two treatment arms: vigorous intensity high 
dose exercise augmentation or health education intervention augmentation. The CTN-0037 
study design has been described in detail elsewhere (Trivedi, Greer, et al., 2011).
Measures
Demographics—Standard demographic information collected included gender, race, 
ethnicity, and education.
Diagnostic assessments—Stimulant use disorders were assessed using the substance 
use modules from the World Health Organization (WHO) Composite International 
Diagnostic Interview (CIDI) (Version 2.1) for DSM-IV-TR stimulant abuse and dependence 
(Robins et al., 1988; WHO, 1997). Diagnostic categories required for study entry included 
one or more of the following: cocaine abuse, cocaine dependence, other stimulant abuse, and 
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other stimulant dependence. Because several participants received more than one diagnosis, 
the sample was grouped into the following categories to collapse the abuse/dependence 
differentiation and better reflect the substance(s) used, as follows: cocaine use disorder only, 
cocaine plus other stimulant use disorder (e.g., methamphetamine), and other stimulant use 
disorder only.
The Mini International Neuropsychiatric Interview (MINI) (Sheehan et al., 1997) was used 
to obtain diagnostic information for other DSM-IV-TR Axis I disorders. The total number of 
current psychiatric disorders was summed for each participant (range, 0–13). Nicotine 
dependence among smokers was evaluated using the Fagerström Test for Nicotine 
Dependence, a 6-item questionnaire with a total score range of 0 to 10, with higher scores 
indicating greater nicotine dependence (Heatherton, Kozlowski, Frecker, & Fagerstrom, 
1999; Kozlowski, Porter, Orleans, Pope, & Heatherton, 1994).
Drug use—Drug, alcohol, and nicotine quantity and frequency were assessed for the 30 
days prior to residential treatment admission using the Timeline Followback method (Sobell 
& Sobell, 1992). The Addiction Severity Index-Lite assessed multiple domains commonly 
affected by substance use, including medical, employment/self-support, alcohol use, drug 
use, legal status, family/social, and psychiatric status (McLellan, Luborsky, Woody, & 
O’Brien, 1980).
Mental health and well being—Risk for suicide and related behaviors was evaluated 
using the Concise Health Risk Tracking–Self-Report, a 14-item participant self-report 
assessment with item responses ranging from 0 (strongly disagree) to 4 (strongly agree) 
(Trivedi, Wisniewski, et al., 2011). A propensity score is derived by summing items 1 to 11, 
resulting in a range of 0 to 44. A risk score is derived by summing items 12 to 14, resulting 
in a range of 0 to 12.
The Short-Form Health Survey (SF-36) was used to assess quality of life and general health 
(Ware, 2003). The SF-36 contains eight subscales measuring the following domains: 
Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social 
Functioning, Role-Emotional, and Mental Health. Subscale scores range from 0 to 100, with 
higher scores indicating better perceived health and functioning. The Mental Health Status 
component score is a weighted average of all of the subscale scores, with the Vitality, Social 
Functioning, Role-Emotional, and Mental Health subscales contributing the most.
The Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Endicott, Nee, 
Harrison, & Blumenthal, 1993) was used to examine participants’ general quality of life. 
Participants rated their satisfaction with the following domains of activity: physical health, 
feelings, work, household duties, school/course work, leisure time activities, and social 
relations. Each item uses a 5-point scale ranging from 1 (very poor) to 5 (very good). The 
raw total score (possible range from 14 to 70) was transformed into a percentage maximum 
possible score with a possible range of 0 to 100. Higher scores indicate greater life 
satisfaction and enjoyment.
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Physical health—Participants completed the Self-Administered Comorbidity 
Questionnaire (Sangha, Stucki, Liang, Fossel, & Katz, 2003), which assesses the presence of 
medical problems, their severity, and whether the condition limits functioning. Participants 
received a maximum of 3 points for each medical condition (1 point for its presence, 1 point 
if they received treatment for the condition, and 1 point if the condition limited activities). 
There were 15 conditions and the option to add 3 additional conditions. The possible score 
range was 0 to 54.
The Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire 
(CPFQ) (Fava et al., 2006) is a 7-item measure of physical well-being and cognitive and 
executive dysfunction. Each item uses a 6-point scale ranging from 1 (greater than normal) 
to 6 (totally absent). The total score is the sum of items a to g, with a range of 7 to 42. 
Higher scores indicate poorer functioning.
The Physical Health Status component score of the SF-36 (Ware, 2003) was used to assess 
physical health. It is a weighted average of all of the subscale scores for Physical 
Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-
Emotional, and Mental Health, with the Physical Functioning, Role-Physical, Bodily Pain, 
and General Health subscales contributing the most. Higher scores indicate perceived better 
health and functioning.
Data Analysis
Bivariate tests for race and ethnic differences at baseline were conducted using chi-square 
and analysis of variance (ANOVA) for categorical and continuous outcomes, respectively. 
Significant chi-square tests were followed by Bonferroni-corrected comparisons between 
each pair of groups. Significant ANOVAs were followed by pair-wise comparisons using 
the Tukey-Kramer test (results not shown and only significant pair-wise comparisons are 
reported in the text). However, because this study is intended to characterize the sample 
using a retrospective analysis of baseline data, no correction was made for the number of 
outcomes examined.
Effect sizes were measured by omega-squared for continuous outcomes and Cramer’s V for 
categorical outcomes. Omega-squared can be interpreted as an estimate of the percent of 
population variance explained by group membership. Therefore, benchmarks from Cohen’s 
d can be applied (Cohen, 1988) where small (d = 0.2), medium (d = 0.5), and large (d = 0.8) 
effects account for 1%, 6%, and 14% of variance explained, respectively. Because Cramer’s 
V can be interpreted as a correlation, we applied Cohen’s benchmarks for correlations and 
regard Cramer’s V of 0.1, 0.3, and 0.5 as small, medium, and large, respectively. 
Multivariate tests were produced by analysis of covariance (ANCOVA) controlling for age, 
gender, and education.
RESULTS
Demographics and Drug Use
The baseline demographic and drug use characteristics for this treatment seeking sample of 
stimulant abusers (N = 290) are presented in Table 1, stratified by race and ethnicity. Black 
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participants were significantly older than Whites or Hispanics (p < .001). Hispanic 
participants were more likely to have less education (p = .014). Gender also varied 
significantly across race and ethnicity (p < .001).
Significant differences between groups were found on drug use characteristics. Black and 
Hispanic participants were more likely to use alcohol (78.1% and 71.0%, respectively) than 
White participants (55.0%) (p < .001). Blacks had higher rates of cocaine use (97.7%) 
versus Whites (63.4%) or Hispanics (67.7%) (p < .001), but lower rates of 
methamphetamine use (3.1%) than Hispanics (35.5%) and especially Whites (47.3%) (p < .
001). Whites had higher rates of other stimulant use (5.3%) than Blacks (0%) (p < .001). 
Whites also used other illicit drugs (32.1%) at higher rates than Blacks (4.7%) and Hispanics 
(9.7%) (p < .001).
Stimulant use diagnoses showed similar differences by race and ethnicity. Black participants 
(91.4%) were more likely than Hispanics (51.6%) to be diagnosed with cocaine abuse or 
dependence only, whereas Whites (28.5%) were least likely to have a cocaine only use 
disorder. Whites (53.1%) and Hispanics (38.7%) were more likely than Blacks (5.5%) to be 
diagnosed with both a cocaine and other stimulant use disorder, whereas Whites (18.5%) 
were more likely than Hispanics (9.7%) and Blacks (3.1%) to be diagnosed with other 
stimulant use disorder only. Blacks were significantly more likely to report smoking cocaine 
(74.8%) than Whites (45.9%) or Hispanics (59.3).
Comorbid Mental Health and Physical Health Conditions
Table 2 describes comorbid conditions across race and ethnic groups, and related mental 
health, physical health, and well-being. On measures of mental health, Black participants 
endorsed fewer psychiatric disorders (mean = 0.7, standard deviation [SD] = 0.9, p = .002) 
and symptoms of depression (mean = 4.2, SD = 2.4, p < .001) than Whites or Hispanics and 
reported a lower risk for suicide (mean = 7.2, SD = 6.0, p = .008) than Whites. Black 
participants reported better mental health status (mean = 47.0, SD = 11.4) than Hispanics 
(mean = 40.0, SD = 13.4) and Whites (mean = 39.3, SD = 14.4, p < .001), as well as better 
quality of life (mean = 72.7, SD = 14.5) than Whites (mean = 65.4, SD = 17.2).
Regarding physical health comorbidities (Table 2), Black participants reported poorer 
physical health status (Blacks: mean = 53.5, SD = 7.6; Whites: mean = 56.2, SD = 6.8; 
Hispanics: mean = 56.6, SD = 7.1; p = .005), and lower cognitive and physical functioning 
than Whites (Blacks; mean = 16.0, SD = 4.9; Whites: mean = 19.6, SD = 7.1; Hispanics: 
mean = 18.0, SD = 5.5; p < .001).
The results of the multivariate analysis are shown in Table 3. After adjusting for age, 
gender, and education, findings for physical health status were no longer significant (p = .
373). All other significant findings remained.
DISCUSSION
In this large, heterogeneous sample of community-based treatment seeking stimulant 
abusers, we found important differences between race and ethnic groups on several mental 
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health, physical health, and wellness measures that could help identify potential areas for 
intervention to improve treatment outcomes. White, Black, and Hispanic participants 
reported varied demographic characteristics, substance use patterns and diagnoses, and 
comorbid mental and physical health conditions. Effect sizes for ethnic differences on 
demographic and substance abuse variables were relatively large compared to those 
associated with comorbid conditions. Blacks were more likely to use alcohol and to be 
diagnosed with a cocaine use disorder only, whereas Whites were more likely to use 
methamphetamines and a variety of other illicit drugs and to be diagnosed with both a 
cocaine and other stimulant use disorder or other stimulant use disorder only. Hispanics, 
similar to Blacks, were more likely to use alcohol, but their rates of methamphetamine use 
and diagnoses for cocaine and other stimulant use disorder or other stimulant use disorder 
only fell in between Whites and Blacks.
These findings are consistent with other studies examining the relationship of race and 
ethnicity to drug use across various settings. An aggregate investigation of self-reported 
drug abuse and dependence from multiple National Household Surveys on Drug Abuse 
showed that Blacks report higher rates of cocaine use by routes with faster absorption (i.e., 
smoking or injection), which are associated with higher rates of dependence (Chen & 
Kandel, 2002). Nearly half of all cocaine-related emergency room episodes in the United 
States in the past decade occurred among Blacks, significantly higher than any other race or 
ethnic group (Chen & Kandel, 2002). Methamphetamine-positive patients in a trauma 
setting were more likely to be White or Hispanic (Schermer & Wisner, 1999) and Blacks in 
rural settings were less likely to use methamphetamine compared to Whites (Borders et al., 
2008), suggesting that our finding of more methamphetamine use among Whites and 
Hispanics is not limited to this treatment-seeking population.
Blacks in this study reported fewer psychiatric disorders and symptoms of depression and 
better mental health status and well-being, consistent with several large studies that found 
lower rates of depression in Blacks compared to other groups (Jonas, Brody, Roper, & 
Narrow, 2003; Kessler et al., 2003). These findings were unexpected given the higher rates 
of reported physical comorbidities and cognitive difficulties observed in this group. 
However, these findings are consistent with other data in which similar differences have 
been attributed to a variety of reasons including underreporting despite using systematic 
measures, differences in expression of depressive symptoms, or true differences in 
prevalence (Alim, Charney, & Mellman, 2006). Underreporting may occur because Blacks 
delay seeking help for mental health concerns or utilize informal behavioral health services 
(K. Davis, 2011).
By contrast, Hispanics and Whites also appeared to have the greatest mental health needs, 
with both reporting more psychiatric disorders and depressive symptoms and Whites 
reporting more risk for suicide, although effect sizes were small. Methamphetamine abuse 
predicts reduced mental health status (Vearrier, Greenberg, Miller, Okaneku, & Haggerty, 
2012) and the reports of poor mental health in Whites and Hispanics in this study may be 
associated with their greater use of methamphetamine, although a causal relationship cannot 
be established. This is consistent with previous findings among mostly White 
methamphetamine users in outpatient treatment who reported more past suicide attempts, 
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had higher rates of mood disorders (primarily major depression), and were twice as likely to 
be prescribed psychiatric medications compared to primary cocaine users (Copeland & 
Sorensen, 2001).
In this study, Black participants reported more comorbid medical conditions, poorer health 
status, and lower physical and cognitive functioning than other groups. These differences 
may be explained by age differences at treatment entry (i.e., Blacks were older) and 
correspond with previous research that found Black clients were least likely to initiate 
substance abuse treatment (Acevedo et al., 2012). Alternative explanations may also include 
barriers to services or poorer quality medical care for Blacks associated with, among other 
factors, a general mistrust of medical providers that arises from historical persecution and 
documented abuse and perceived mistreatment in health care settings because of racial 
background (U.S. Department of Health and Human Services, 2001).
Physical health conditions could also be associated with the effects of cocaine or alcohol use 
in Blacks and linked directly to the toxicity of each drug (Corrao, Bagnardi, Zambon, & La 
Vecchia, 2004; Stein, 1999) or route of drug administration (e.g., smoking of crack cocaine) 
(Winger, Woods, & Hofmann, 2004). However, explanations for race and ethnic differences 
in physical health associated with drug of choice may be weaker than other possible 
explanations because methamphetamine abusers (mostly White and Hispanic in this sample) 
experience numerous medical conditions (Panenka et al., 2013) and cocaine and 
methamphetamine use are both related to impaired cognitive functions (Simon et al., 2002).
There are limitations to this study that should be noted. The study was a retrospective 
assessment of baseline substance abuse and mental and physical health measures collected. 
Future studies should prospectively aim to better clarify the relationships between these 
disorders, substance use, and comorbid conditions. In addition, the data are self-report, 
which may be subject to recall bias, although the time periods assessed for most measures 
were relatively short (7–30 days). The eligibility criteria were also somewhat restricted in 
that individuals with physical issues or illnesses that would preclude exercise or those with 
psychiatric safety concerns were not eligible, thus potentially restricting information on 
physical and psychiatric health. Participants also had to be interested and willing to exercise, 
which may reduce generalizability to the larger treatment-seeking population.
Alternatively, a major strength is that the data for this study come from a sample of 
stimulant abusers seeking community-based addiction treatment across a geographically 
diverse set of community treatment providers. Thus, results may generalize to a broader 
clinical sample. This baseline study also adds to the current research literature because racial 
and ethnic minority populations are underrepresented in clinical trials. There is less 
information available about the treatment needs of minority groups, even more so for racial 
and ethnic minority stimulant abusers. Racial and ethnic groups have different patterns of 
substance use, which may impact their risk for comorbid mental and physical health 
conditions, as well as their risk for relapse after treatment.
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CONCLUSION
Furthermore, these findings offer implications for stimulant abuse treatment. They highlight 
the usefulness of integrating mental and physical health services into substance abuse 
treatment programs serving racially and ethnically diverse patients. Receipt of primary 
medical care is associated with lower addiction severity and suggests that efforts to link 
treatment seeking substance abusers to primary medical care services should be considered 
(Saitz, Horton, Larson, Winter, & Samet, 2005). Integrating mental and physical health care 
into substance abuse treatment while paying attention to differences in racial and ethnic 
groups, who have varying comorbid drug use, mental health, and medical needs, could have 
a substantial impact on treatment outcomes.
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